Immunohistochemical expression of MDR1-Pgp 170 in canine cutaneous and oral melanomas: pattern of expression and association with tumour location and phenotype

Vet Comp Oncol. 2017 Dec;15(4):1393-1402. doi: 10.1111/vco.12281. Epub 2016 Oct 25.

Abstract

Canine melanoma (CMM) more commonly affects the oral mucosa and the cutis. CMM shares several features with human melanomas (HMM), included resistance to a broad variety of antineoplastic chemotherapy agents. P-glycoprotein 1 (Pgp) expression is a well-recognized feature of multi-drug resistance and the purpose of this study was to investigate its expression in treatment naïve CMM. We also investigated Pgp association with tumour location and histological features. Histology records of CMM were retrieved, including patients from 2012-2014. Twenty-five cases of CMM were included in this study. Results revealed that Pgp is expressed in CMM and oral tumours were more likely to have a membranous Pgp expression (100%) than cutaneous tumours (66.6%) (P = 0.010). Cytoplasmic and nuclear Pgp expression could also be identified. Results of this study bring useful data that help in understanding one of the possible mechanisms responsible of intrinsic chemotherapy resistance in canine CMM.

Keywords: MDR1; Pgp170; canine cutaneous melanoma; canine oral melanoma.

MeSH terms

  • ATP Binding Cassette Transporter, Subfamily B, Member 1 / metabolism*
  • Animals
  • Dog Diseases / metabolism*
  • Dog Diseases / pathology
  • Dogs
  • Female
  • Male
  • Melanoma / metabolism
  • Melanoma / pathology
  • Melanoma / veterinary*
  • Mouth Neoplasms / metabolism
  • Mouth Neoplasms / pathology
  • Mouth Neoplasms / veterinary*
  • Skin Neoplasms / metabolism
  • Skin Neoplasms / pathology
  • Skin Neoplasms / veterinary*

Substances

  • ATP Binding Cassette Transporter, Subfamily B, Member 1